161 related articles for article (PubMed ID: 8631768)
21. The significance of fibrin binding by plasminogen activator inhibitor 1 for the mechanism of tissue-type plasminogen activator-mediated fibrinolysis.
Stringer HA; Pannekoek H
J Biol Chem; 1995 May; 270(19):11205-8. PubMed ID: 7744752
[TBL] [Abstract][Full Text] [Related]
22. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability.
Lawrence DA; Olson ST; Palaniappan S; Ginsburg D
Biochemistry; 1994 Mar; 33(12):3643-8. PubMed ID: 8142362
[TBL] [Abstract][Full Text] [Related]
23. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
De Taeye B; Gils A; Vleugels N; Rabijns A; Declerck PJ
Biochem Biophys Res Commun; 2004 Aug; 321(3):746-51. PubMed ID: 15358169
[TBL] [Abstract][Full Text] [Related]
24. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1.
Gils A; Declerck PJ
J Biol Chem; 1997 May; 272(19):12662-6. PubMed ID: 9139722
[TBL] [Abstract][Full Text] [Related]
25. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
Keijer J; Ehrlich HJ; Linders M; Preissner KT; Pannekoek H
J Biol Chem; 1991 Jun; 266(16):10700-7. PubMed ID: 1709939
[TBL] [Abstract][Full Text] [Related]
26. Localization of vitronectin binding domain in plasminogen activator inhibitor-1.
Lawrence DA; Berkenpas MB; Palaniappan S; Ginsburg D
J Biol Chem; 1994 May; 269(21):15223-8. PubMed ID: 7515053
[TBL] [Abstract][Full Text] [Related]
27. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.
Ehrlich HJ; Gebbink RK; Keijer J; Linders M; Preissner KT; Pannekoek H
J Biol Chem; 1990 Aug; 265(22):13029-35. PubMed ID: 1695900
[TBL] [Abstract][Full Text] [Related]
28. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
[TBL] [Abstract][Full Text] [Related]
29. Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule.
Sui GC; Wiman B
Biochem J; 1998 Apr; 331 ( Pt 2)(Pt 2):409-15. PubMed ID: 9531478
[TBL] [Abstract][Full Text] [Related]
30. Combinatorial mutagenesis of the reactive site region in plasminogen activator inhibitor I.
York JD; Li P; Gardell SJ
J Biol Chem; 1991 May; 266(13):8495-500. PubMed ID: 2022663
[TBL] [Abstract][Full Text] [Related]
31. Biochemical and biophysical studies of reactive center cleaved plasminogen activator inhibitor type 1. The distance between P3 and P1' determined by donor-donor fluorescence energy transfer.
Aleshkov SB; Fa M; Karolin J; Strandberg L; Johansson LB; Wilczynska M; Ny T
J Biol Chem; 1996 Aug; 271(35):21231-8. PubMed ID: 8702896
[TBL] [Abstract][Full Text] [Related]
32. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin.
Fa M; Karolin J; Aleshkov S; Strandberg L; Johansson LB; Ny T
Biochemistry; 1995 Oct; 34(42):13833-40. PubMed ID: 7577977
[TBL] [Abstract][Full Text] [Related]
33. Mutational and immunochemical analysis of plasminogen activator inhibitor 1.
Shubeita HE; Cottey TL; Franke AE; Gerard RD
J Biol Chem; 1990 Oct; 265(30):18379-85. PubMed ID: 2120233
[TBL] [Abstract][Full Text] [Related]
34. Phage display of the serpin alpha-1 proteinase inhibitor randomized at consecutive residues in the reactive centre loop and biopanned with or without thrombin.
Scott BM; Matochko WL; Gierczak RF; Bhakta V; Derda R; Sheffield WP
PLoS One; 2014; 9(1):e84491. PubMed ID: 24427287
[TBL] [Abstract][Full Text] [Related]
35. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
[TBL] [Abstract][Full Text] [Related]
36. Characterisation of the complex of plasminogen activator inhibitor type 1 with tissue-type plasminogen activator by mass spectrometry and size-exclusion chromatography.
Strömqvist M; Karlsson KE; Björquist P; Andersson JO; Byström M; Hansson L; Johansson T; Deinum J
Biochim Biophys Acta; 1996 Jun; 1295(1):103-9. PubMed ID: 8679667
[TBL] [Abstract][Full Text] [Related]
37. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1).
van Meijer M; Gebbink RK; Preissner KT; Pannekoek H
FEBS Lett; 1994 Oct; 352(3):342-6. PubMed ID: 7523190
[TBL] [Abstract][Full Text] [Related]
38. Purification of storage granule protein-23. A novel protein identified by phage display technology and interaction with type I plasminogen activator inhibitor.
Lang IM; Chuang TL; Barbas CF; Schleef RR
J Biol Chem; 1996 Nov; 271(47):30126-35. PubMed ID: 8939962
[TBL] [Abstract][Full Text] [Related]
39. Interaction of wild-type and catalytically inactive mutant forms of tissue-type plasminogen activator with human umbilical vein endothelial cell monolayers.
Ramakrishnan V; Sinicropi DV; Dere R; Darbonne WC; Bechtol KB; Baker JB
J Biol Chem; 1990 Feb; 265(5):2755-62. PubMed ID: 2105933
[TBL] [Abstract][Full Text] [Related]
40. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition.
Lawrence DA; Olson ST; Palaniappan S; Ginsburg D
J Biol Chem; 1994 Nov; 269(44):27657-62. PubMed ID: 7961684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
